Drugs / Zastaprazan
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT07467213 | Jun 2026 → Dec 2029 expected | acute myocardial infarction | Samsung Medical Center | Recruiting | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07471867 | Apr 2026 → Jul 2028 expected | coronary artery disorder | Yonsei University | Recruiting | No outcome recorded |
| Phase 4 | NCT07115173 | Dec 2025 → Jun 2027 expected | Helicobacter pylori infectious disease | Samsung Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07268820 | Jul 2025 → May 2026 overdue | gastroesophageal reflux disease | Incheon St.Mary's Hospital | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07691242 Comparator | Sep → Dec 2026 expected | — | Daewon Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zastaprazan | “Zastaprazan 20mg” NCT07691242 ↗ |
| Route | Oral | “preferably administered orally in the morning before breakfast” NCT07268820 ↗ |